Sana appoints Douglas Williams as President of R&D and Gary Meininger as CMO; CMO Sunil Agarwal departs

Sana Biotechnology, Inc.

Douglas Williams, Ph.D., appointed EVP & President, R&D effective April 10, 2023; previously CEO of Codiak BioSciences.
Gary Meininger, M.D., appointed Chief Medical Officer; previously SVP, Head of Clinical Development at Vertex.
Sunil Agarwal, M.D., resigns as CMO effective April 10, 2023; will remain employee through April 28 for transition.
Williams receives $580,000 base salary, 40% target bonus, and option to purchase 1,100,000 shares of common stock.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sunil Agarwal

Executive Vice President, Head of Development, and Chief Medical Officer

SANA · Sana Biotechnology, Inc.

Effective: 2023-04-10
Filed: April 10, 2023, 7:59 PM ET

Sunil Agarwal, M.D. resigned from his position as Executive Vice President, Head of Development, and Chief Medical Officer of the Company, effective as of April 10, 2023.

Appointed

Douglas E. Williams

Executive Vice President and President, Research and Development

SANA · Sana Biotechnology, Inc.

Effective: 2023-04-10
Filed: April 10, 2023, 7:59 PM ET

Douglas E. Williams, Ph.D., has been appointed and will join the Company as Executive Vice President and President, Research and Development, effective April 10, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sunil Agarwal resigned as Executive Vice President, Head of Development, and Chief Medical Officer at Sana Biotechnology, Inc..

Action: resigned
Role: Executive Vice President, Head of Development, and Chief Medical Officer

Exact text from the filing

Sunil Agarwal, M.D. resigned from his position as Executive Vice President, Head of Development, and Chief Medical Officer of the Company, effective as of April 10, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Douglas E. Williams was appointed as Executive Vice President and President, Research and Development at Sana Biotechnology, Inc..

Action: appointed
Role: Executive Vice President and President, Research and Development

Exact text from the filing

Douglas E. Williams, Ph.D., has been appointed and will join the Company as Executive Vice President and President, Research and Development, effective April 10, 2023.

View on SEC.gov

Sana Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-23-005548

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.